Meme penny stocks are a budding sector; have you heard of these 4?
The post 4 Meme Penny Stocks To Watch As DogeCoin Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Are These Meme Penny Stocks On Your Under $5 List?
We’ve all heard the terms, Reddit penny stocks, meme stocks, and any other popular trends that have come up this year. And if you’re new to penny stocks, these are some of the biggest trends in the market right now.
For those unfamiliar, let’s talk about these briefly. Reddit penny stocks are a trend that has come up ever since GameStop (NYSE: GME) shot up in the triple-digit percentage points after almost declaring bankruptcy earlier this year. This was a coordinated effort by traders on the social media site Reddit and specifically in the subreddit, R/wallstreetbets.
For the first time, a community came together to invest in a company, not because of its fundamentals, but because they couldn’t stand to see a piece of their childhood be shorted to non-existence. So, these traders decided to all buy-in and beat out a massive short position held by a large hedge fund.
While this was a big deal when it happened, it has had an even larger effect months later. We witnessed a complete paradigm shift, illustrating just how influential retail traders can be.
The term ‘meme stocks’ also coincides with this, but there are other aspects to understand. Meme stocks on its own implies a company that has come to light as a trending or viral topic. A meme is an image or video depicting a usually comedically approached topic. If you go on the internet, you’ve probably seen photos of cats with words beneath it. This is a meme.
So, adding the layer of penny stocks to that has brought many trending companies further into the spotlight. This includes the likes of Tesla Inc. (NASDAQ: TSLA) or AMC Entertainment Holdings Inc. (NYSE: AMC). The rise of meme stocks is a direct result of the influence of investors on Reddit or other social media websites.
These stocks can quickly increase (or drop) in value in a very short period. While the volatility of these penny stocks to watch can dissuade some, others see large potential in them. Considering all of this, let’s take a look at four Reddit penny stocks for your May watchlist.
The final company on this list, Auris Medical Holding Ltd., is a biotech penny stock. This biotech company creates therapeutics for unmet medical needs in multiple fields. These fields include neurotology, rhinology, and allergy. Right now it has Phase 3 programs for Keyzilen (AM-101) to treat inner ear tinnitus, and Sonsuvi (AM-111) to treat inner ear hearing loss. It has multiple other trials taking place at the moment as well.
On May 7th, Auris provided an update on its Bentrio nasal spray used to treat allergic rhinitis. Bentrio is reported to have met the primary efficacy endpoint in its clinical evaluation. It reduces significant nasal symptoms in a fast and effective way. Now the company has a pre-submission meeting with the U.S. Food and Drug Administration (FDA). If Bentrio is approved by the FDA, it could be very big for Auris.
After this update was released, EARS stock increased by more than 15% on May 7th to $3.30 a share on average. At one point in early trading, EARS stock touched $4.34 a share.
With numbers like this, could Auris escape the penny stock category altogether upon an FDA approval? Time will tell what happens to EARS stock, but what we do know is this company has extremely high volume at the moment. With this in mind, will this company make your penny stock watch list?
Peabody Energy Corp. (NYSE: BTU)
While Peabody Energy climbed out of penny stock territory only a day ago, it’s still worth mentioning for its sizable rises in value. To understand why BTU stock has climbed so heavily in the past few months, let’s take a closer look at what the company does.
Peabody is a leading energy stock and coal producer working to provide products used in the production of electricity in both emerging and developed countries. Its products provide the energy to produce everything from steel and other infrastructure-related products.
Additionally, the company states that it is heavily committed to sustainability in all of its operations. Only a week or so ago, BTU announced its Q1 2021 financial results for the period ended on March 31st. In the results, revenue hit a solid $651.3 million with a net income of $77.6 million. While it did take in an EPS loss of $0.79, this makes sense given the large effects of the pandemic on the energy industry.
“While economies across the globe are in varying stages of recovery from the ongoing pandemic, I’m pleased to note that operational and productivity improvements continue to take hold across the company. In addition, we successfully completed our refinancing activities and subsequently repaid a portion of our long-term debt.
Looking ahead, we remain focused on further improving our seaborne metallurgical cost structure and capturing continued cash improvements across the organization while positioning for ongoing seaborne market improvements.”
CEO of Peabody Energy Corp., Glenn Kellow
So as the pandemic winds down in severity, will BTU be on your list of penny stocks to watch?
Checkpoint Therapeutics Inc. (NASDAQ: CKPT)
Checkpoint Therapeutics Inc. is a penny stock that we’ve covered numerous times in the past few months. As a biotech stock, CKPT has seen a lot of bullish momentum as a result of the pandemic. Similar to BTU, Checkpoint recently announced its first-quarter 2021 financial results as well as some corporate highlights. For some context, CKPT is a clinical-stage immunotherapy and oncology-focused company working on several novel therapeutics.
This includes its lead candidate, cosibelimab, which is an anti-PD-L1 anybody licensed from the Dana Farber Cancer Institute. This compound is in a Phase 1 clinical trial for its potential in treating certain metastatic cancers. Additionally, Checkpoint is studying its CK-101 molecule for its potential in treating non-small cell lung cancer. It’s worth noting that Checkpoint was founded a while ago by Fortress Biotech (NASDAQ: FBIO), which adds another interesting layer to the company.
In its Q1 results, CEO James Oliviero, stated that “we continued to advance the development of our two lead drug candidates while also enhancing our cash position. Enrollment in our registration-enabling study for cosibelimab in metastatic cutaneous squamous cell carcinoma is nearly complete and the stay remains on track to report top-line results by year-end.”
Financially, the company ended the quarter with more than $23 million in net proceeds from its at-the-market stock issuance. This brought its total cash position to roughly $60 million. With a net loss of $6.5 million, it looks like CKPT is in an advantageous position as far as its free cash is concerned. Whether it deserves a place on your list of penny stocks, however, is up to you.
Ebang International Holdings Inc. (NASDAQ: EBON)
Ebang International Holdings seems to be more of a meme stock than many others. This is due to its pure-play relationship with the cryptocurrency market. Interestingly enough, Ebang reportedly mines both Bitcoin and DogeCoin among others and operates completely vertically. It has a large range of mining operations underway that include the two cryptos mentioned above as well as Litecoin.
Because of this, its price tends to rise and fall with the price of these popular cryptocurrencies. Considering that it is one of the only publicly traded companies with direct ties to DogeCoin, many Reddit penny stock investors have found solace with EBON stock.
However, it’s also worth mentioning that because of its ties to this, EBON stock tends to be highly volatile. While it is directly considered a blockchain penny stock, its underlying business is in the mining of cryptocurrency, which is somewhat separate.
Additionally, Ebang works in the production of application-specific integrated circuits (ASICs), which help in the mining of Bitcoin and other cryptocurrencies. While these coins have shown large price swings in the past few weeks, many believe in the long-term future and potential of cryptocurrency as a whole. So while EBON is fluctuating on a large level, it could be worth keeping an eye on for these reasons.
Are Meme Penny Stocks The Right Choice?
The short answer is that it truly depends on your investing style. While meme stocks or penny stocks, in general, are not for everyone, with the right tools, anyone can have a chance at making profits in the market.
But, it’s always important to consider your risk tolerance as well as what your investing goals are. This is the best and only way to align your portfolio with the right penny stocks to buy. Now, with meme stocks and Reddit penny stocks, volatility is often much higher than others. This is constant, and something that is also desirable for investors. Considering all of this, are meme penny stocks the right choice for you?
Pharma industry reputation remains steady at a ‘new normal’ after Covid, Harris Poll finds
The pharma industry is hanging on to reputation gains notched during the Covid-19 pandemic. Positive perception of the pharma industry is steady at 45%…
The pharma industry is hanging on to reputation gains notched during the Covid-19 pandemic. Positive perception of the pharma industry is steady at 45% of US respondents in 2023, according to the latest Harris Poll data. That’s exactly the same as the previous year.
Pharma’s highest point was in February 2021 — as Covid vaccines began to roll out — with a 62% positive US perception, and helping the industry land at an average 55% positive sentiment at the end of the year in Harris’ 2021 annual assessment of industries. The pharma industry’s reputation hit its most recent low at 32% in 2019, but it had hovered around 30% for more than a decade prior.
Rob Jekielek
“Pharma has sustained a lot of the gains, now basically one and half times higher than pre-Covid,” said Harris Poll managing director Rob Jekielek. “There is a question mark around how sustained it will be, but right now it feels like a new normal.”
The Harris survey spans 11 global markets and covers 13 industries. Pharma perception is even better abroad, with an average 58% of respondents notching favorable sentiments in 2023, just a slight slip from 60% in each of the two previous years.
Pharma’s solid global reputation puts it in the middle of the pack among international industries, ranking higher than government at 37% positive, insurance at 48%, financial services at 51% and health insurance at 52%. Pharma ranks just behind automotive (62%), manufacturing (63%) and consumer products (63%), although it lags behind leading industries like tech at 75% positive in the first spot, followed by grocery at 67%.
The bright spotlight on the pharma industry during Covid vaccine and drug development boosted its reputation, but Jekielek said there’s maybe an argument to be made that pharma is continuing to develop innovative drugs outside that spotlight.
“When you look at pharma reputation during Covid, you have clear sense of a very dynamic industry working very quickly and getting therapies and products to market. If you’re looking at things happening now, you could argue that pharma still probably doesn’t get enough credit for its advances, for example, in oncology treatments,” he said.
The COVID pandemic transformed our lives in ways many of us are still experiencing, four years later. One of these changes was the significant uptake in gaming as a hobby, chief among them being “cosy games” like Animal Crossing: New Horizons (2020).
Players sought comfort in these wholesome virtual worlds, many of which allowed them to socialise from the safety of their homes. Cosy games, with their comforting atmospheres, absence of winning or losing, simple gameplay, and often heartwarming storylines provided a perfect entry point for a new hobby. They also offered predictability and certainty at a time when there wasn’t much to go around.
Cosy games are often made by small, independent developers. “Indie games” have long been evangelised as the purest form of game development – something anyone can do, given enough perseverance. This means they can provide an entry point for creators who hadn’t made games before, but were nevertheless interested in it, enabling a new array of diverse voices and stories to be heard.
In May 2020, near the start of the pandemic, the small poetry game A Solitary Spacecraft, which was about its developer’s experience of their first few months in lockdown, was lauded as particularly poignant. Such games showcase a potential angle for effective cosy game development: a personal one.
Personal themes are often explored through cosy games. For instance, Chicory and Venba (both released in 2023) tackle difficult topics like depression and immigration, despite their gorgeous aesthetics. This showcases the diversity of experiences on display within the medium.
Historically, restructurings like these, or discontent with working conditions, have led talented laid-off developers to create their own companies and explore indie development. In the wake of the pandemic and the cosy game boom, these developers may have more personal stories to tell.
Making my own cosy game
I developed my own cosy and personal game during the pandemic and quickly discovered that creating these games in a post-lockdown landscape is no mean feat.
What We Take With Us (2023) merges reality and gameplay across various digital formats: a website, a Discord server that housed an online alternate reality game and a physical escape room. I created the game during the pandemic as a way to reflect on my journey through it, told through the videos of game character Ana Kirlitz.
The trailer for my game, What We Take With Us.
Players would follow in Ana’s footsteps by completing a series of ten tasks in their real-world space, all centred on improving wellbeing – something I and many others desperately needed during the pandemic.
But creating What We Take With Us was far from straightforward. There were pandemic hurdles like creating a physical space for an escape room amid social distancing guidelines. And, of course, the emotional difficulties of wrestling with my pandemic journey through the game’s narrative.
These struggles were starkly contrasted by the feedback I received from players who played the game, however.
This is a crucial lesson for indie developers: the creator’s journey and the player’s experience are often worlds apart. Cosy, personal games, as I discovered, can change the lives of those who play them, no matter how few they reach. They can fundamentally change the way we think about games, allow us to reconnect with old friends, or even inspire us to change careers – all real player stories.
Lessons in cosy game development
I learned so much about how cosy game development can be made more sustainable for creators navigating the precarious post-lockdown landscape. This is my advice for other creators.
First, collaboration is key. Even though many cosy or personal games (like Stardew Valley) are made by solo creators, having a team can help share the often emotional load. Making games can be taxing, so practising self-care and establishing team-wide support protocols is crucial. Share your successes and failures with other developers and players. Fostering a supportive community is key to success in the indie game landscape.
Second, remember that your game, however personal, is a product – not a reflection of you or your team. Making this distinction will help you manage expectations and cope with feedback.
Third, while deeply considering your audience may seem antithetical to personal projects, your game will ultimately be played by others. Understanding them will help you make better games.
The pandemic reignited the interest in cosy games, but subsequent industry-wide troubles may change games, and the way we make them, forever. Understanding how we make game creation more sustainable in a post-lockdown, post-layoff world is critical for developers and players alike.
For developers, it’s a reminder that their stories, no matter how harrowing, can still meaningfully connect with people. For players, it’s an invitation to embrace the potential for games to tell such stories, fostering empathy and understanding in a world that greatly needs it.
Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.
Adam Jerrett does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
The SNF Institute for Global Infectious Disease Research announces new advisory board
From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in…
From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in the 1970s, combating infectious disease has a rich history at Rockefeller. That tradition continues as the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller University (SNFiRU) caps a successful first year with the establishment of a new advisory board.
Credit: Lori Chertoff/The Rockefeller University
From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in the 1970s, combating infectious disease has a rich history at Rockefeller. That tradition continues as the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller University (SNFiRU) caps a successful first year with the establishment of a new advisory board.
This international advisory board was created in part to give guidance on how to best use SNFiRU’s resources, as well as bring forward innovative ideas concerning new avenues of research, public education, community engagement, and partnership projects.
SNFiRU was established to strengthen readiness for and response to future health crises, building on the scientific advances and international collaborations forged in the context of the COVID-19 pandemic. Launched with a $75 million grant from the Stavros Niarchos Foundation (SNF) as part of its Global Health Initiative (GHI), the institute provides a framework for international scientific collaboration to foster research innovations and turn them into practical health benefits.
SNFiRU’s mission is to better understand the agents that cause infectious disease and to lower barriers to treatment and prevention globally. To speed this work, the institute launched numerous initiatives in its inaugural year. For instance, SNFiRU awarded 31 research projects in 29 different Rockefeller laboratories for over $5 million to help get collaborative new research efforts off the ground. SNFiRU also supports the Rockefeller University Hospital, where clinical studies are conducted, and brought on board its first physician-scientist through Rockefeller’s Clinical Scholars program. “One of the surprises was the scope of interest from Rockefeller scientists in using their talents to tackle important infectious disease problems,” says Charles M. Rice, Maurice R. and Corinne P. Greenberg Professor in Virology at Rockefeller and director of SNFiRU. “The research topics range from the biology of infectious agents to the dynamics of the immune response to pathogens, and also include a number of infectious disease-adjacent studies.”
In the past 12 months, SNFiRU often brought together scientists studying different aspects of infectious disease as a way to spur new collaborations. In addition to hosting its first annual day-long symposium, SNFiRU initiated a Young Scientist Forum for students and post-doctoral fellows to meet regularly, facilitating cross-laboratory thinking. A bimonthly seminar series has also been established on campus.
Another aim of SNFiRU is to develop relationships with community-based organizations, as well as design and participate in community-engaged research, with a focus on low-income and minority communities. To that end, SNFiRU is helping develop a research project on Chagas disease, a tropical parasitic infection prevalent in Latin America that can cause congestive heart failure and gastrointestinal complications if left untreated. The project will bring together clinicians practicing at health centers in New York, Florida, Texas, and California and basic scientists from multiple institutions to help the communities that are most impacted.
“The SNFiRU international advisory board convenes globally recognized leaders with distinguished biomedical expertise, unrivalled experience in pandemic preparedness and response, and a shared commitment to translating scientific advancements into equitably distributed benefits in real-world settings,” says SNF Co-President Andreas Dracopoulos. “The advisory board will advance the institute’s indispensable mission, which SNF is proud to support as a key part of our Global Health Initiative, and we look forward to seeing breakthroughs in the lab drive better outcomes in lives around the globe.”
The new advisory board will hold its first meeting on April 11th, 2024, following the second annual SNF Institute for Global Infectious Disease Research Symposium at Rockefeller.
Its members are: Rafi Ahmed of Emory University School of Medicine, Cori Bargmann of The Rockefeller University, Yasmin Belkaid of the Pasteur Institute, Anthony S. Fauci, the former director of the National Institute of Allergy and Infectious Diseases, Peter Hotez of Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development, Esper Kallas of of the Butantan Institute, Sharon Lewin of the University of Melbourne Doherty Institue, Carl Nathan of Weill Cornell Medicine, Rino Rappuoli of Fondazione Biotecnopolo di Siena and University of Siena, and Herbert “Skip” Virgin of Washington University School of Medicine and UT Southwestern Medical Center.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
